AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core R&D expense (% of total revenue) by Year
Core R&D expense (% of total revenue) (%)
AstraZeneca Core R&D expense (% of total revenue): 24.0% in FY2025.
Latest, FY2025
24.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 6-K FY2025Q4 Earnings Release
Where the FY2025 figure comes from
“|| - R&D % of Total Revenue | 24% | 24% | -1pp | -1pp”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Core Financial Measures.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core R&D expense (% of total revenue) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Core R&D expense (% of total revenue) (%), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-rd-rev-pct
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.